These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 23171020

  • 1. Both combined oral azithromycin plus allopurinol and intramuscular Glucantime yield low efficacy in the treatment of Old World cutaneous leishmaniasis: a randomized controlled clinical trial.
    Dastgheib L, Naseri M, Mirashe Z.
    Int J Dermatol; 2012 Dec; 51(12):1508-11. PubMed ID: 23171020
    [Abstract] [Full Text] [Related]

  • 2. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T.
    Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
    [Abstract] [Full Text] [Related]

  • 4. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
    Sadeghian G, Nilforoushzadeh MA.
    Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, Juarez M, Taranto NJ.
    Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ, Aminjavaheri M.
    Eur J Dermatol; 2003 Oct; 13(1):40-3. PubMed ID: 12609780
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R, Handjani F, Nouhpisheh MK.
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [Abstract] [Full Text] [Related]

  • 10. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
    Rajabi O, Layegh P, Hashemzadeh S, Khoddami M.
    Dermatol Ther; 2016 Sep; 29(5):358-363. PubMed ID: 27073044
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
    Mohammadzadeh M, Behnaz F, Golshan Z.
    J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
    [Abstract] [Full Text] [Related]

  • 12. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
    Esfandiarpour I, Dabiri SH.
    Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170
    [Abstract] [Full Text] [Related]

  • 13. Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil.
    Toledo Junior A, Daher AB, Amaral TA, Carvalho SF, Romero GA, Rabello A.
    Rev Soc Bras Med Trop; 2014 Aug; 47(6):756-62. PubMed ID: 25626655
    [Abstract] [Full Text] [Related]

  • 14. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
    Shanehsaz SM, Ishkhanian S.
    Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
    [Abstract] [Full Text] [Related]

  • 15. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I, Alavi A.
    Int J Dermatol; 2002 Aug; 41(8):521-4. PubMed ID: 12207774
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
    Munir A, Janjua SA, Hussain I.
    Acta Dermatovenerol Croat; 2008 Aug; 16(2):60-4. PubMed ID: 18541100
    [Abstract] [Full Text] [Related]

  • 17. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
    Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J.
    Ann Intern Med; 1997 Feb 01; 126(3):232-6. PubMed ID: 9027276
    [Abstract] [Full Text] [Related]

  • 18. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
    Pourmohammadi B, Motazedian MH, Handjani F, Hatam GH, Habibi S, Sarkari B.
    Southeast Asian J Trop Med Public Health; 2011 May 01; 42(3):502-8. PubMed ID: 21706927
    [Abstract] [Full Text] [Related]

  • 19. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
    Momeni AZ, Reiszadae MR, Aminjavaheri M.
    Int J Dermatol; 2002 Jul 01; 41(7):441-3. PubMed ID: 12121563
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis.
    Firdous R, Yasinzai M, Ranja K.
    Int J Dermatol; 2009 Jul 01; 48(7):758-62. PubMed ID: 19570087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.